Citations

Showing 10 of 108081 citations.

Proceedings of the 2022 NHLBI and OASH state of the science in transfusion medicine symposium
Custer, Brian , Bloch, Evan M. , Bryant, Barbara J. , D’Alessandro, Angelo , Delaney, Meghan , Goel, Ruchika , Hod, Eldad A. , Josephson, Cassandra D. , Katz, Louis M. , Miller, Yvette Marie , Sayers, Merlyn , Seheult, Jansen N. , Triulzi, Darrell J., Berger, James J., Zou, Shimian , Hailu, Benyam, Glynn, Simone A. , Sayers, Merlyn H , Goel, Ruchika , Custer, Brian S , Seheult, Jansen N , Roubinian, Nareg H.

Mayo Clinic

Transfusion | April 3, 2023 | Volume: 63 | Issue: 5 | Pages: 1074-1091

10.1111/trf.17296 | PMID 37005871 Get It

AbstractBackgroundState of the Science (SoS) meetings are used to define and highlight important unanswered scientific questions. The National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, and the Office of the Assistant Secretary for Health (OASH), Department of Health and Human Services held a virtual SoS in transfusion medicine (TM) symposium.Study Design and MethodsIn advance of the symposium, six multidisciplinary working groups (WG) convened to define research priorities in the areas of: blood donors and the supply, optimizing transfusion outcomes for recipients, emerging infections, mechanistic aspects of components and transfusion, new computational methods in transfusion science, and impact of health disparities on donors and recipients. The overall objective was to identify key basic, translational, and clinical research questions that will help to increase and diversify the volunteer donor pool, ensure safe and effective transfusion strategies for recipients, and identify which blood products from which donors best meet the clinical needs of specific recipient populations.ResultsOn August 29–30, 2022, over 400 researchers, clinicians, industry experts, government officials, community members, and patient advocates discussed the research priorities presented by each WG. Dialogue focused on the five highest priority research areas identified by each WG and included the rationale, proposed methodological approaches, feasibility, and barriers for success.DiscussionThis report summarizes the key ideas and research priorities identified during the NHLBI/OASH SoS in TM symposium. The report highlights major gaps in our current knowledge and provides a road map for TM research.
A distinctive IgG-mediated pathogenesis for primary progressive multiple sclerosis?
Guo, Yong , Lennon, Vanda A.

Mayo Clinic

Brain | April 3, 2023 | Volume: 146 | Issue: 5 | Pages: 1737-1739

10.1093/brain/awad107 | PMID 37006119 Get It

This scientific commentary refers to ‘Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic’ by Wong et al. (https://doi.org/10.1093/brain/awad031).
Three-dimensional printing accuracy analysis for medical applications across a wide variety of printers
Chen, Joshua Ray , Wentworth, Adam, Sears, Victoria A. , Duit, Andrew, Erie, Eric, McGee, Kiaran P. , Morris, Jonathan , Sears, Victoria, McGee, Kiaran , Leng, Shuai , Morris, Jonathan M. , Leng, Shuai

Mayo Clinic

Journal of Medical Imaging | April 3, 2023 | Volume: 10 | Issue: 02 | Pages: No page available

10.1117/1.jmi.10.2.026501 | PMID 37020530 Get It

Is the Gut Microbiome Implicated in the Excess Risk of Hypertension Associated with Obstructive Sleep Apnea? A Contemporary Review
Munir, Sanah S., Singh, Prachi , Covassin, Naima , Sert Kuniyoshi, Fatima H, Singh, Prachi , Kuniyoshi, Fatima H. Sert

Mayo Clinic

Antioxidants | April 3, 2023 | Volume: 12 | Issue: 4 | Pages: 866

10.3390/antiox12040866 | PMID 37107242 Get It

Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder and an established risk factor for cardiovascular diseases, including hypertension. The pathogenesis of elevated blood pressure (BP) in OSA is multifactorial, including sympathetic overdrive, vascular aberrations, oxidative stress, inflammation, and metabolic dysregulation. Among the mechanisms potentially involved in OSA-induced hypertension, the role of the gut microbiome is gaining increasing attention. Perturbations in the diversity, composition, and function of the gut microbiota have been causally linked to numerous disorders, and robust evidence has identified gut dysbiosis as a determinant of BP elevation in various populations. In this brief review, we summarize the current body of literature on the implications of altered gut microbiota for hypertension risk in OSA. Data from both preclinical models of OSA and patient populations are presented, and potential mechanistic pathways are highlighted, along with therapeutic considerations. Available evidence suggests that gut dysbiosis may promote the development of hypertension in OSA and may thus be a target for interventions aimed at attenuating the adverse consequences of OSA in relation to cardiovascular risk.
Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
Ali, Sasha Saadia, Naveen, R, Sen, Parikshit , Day, Jessica , Joshi, Mrudula , Nune, Arvind , Nikiphorou, Elena , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Jagtap, Kshitij , Parodis, Ioannis , Kuwana, Masataka , Makol, Ashima , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, for the COVAD Study, Kardeş, Sinan , Lini, Daniele , Schreiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit , Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Giollo, Alessandro , Alluno, Alessia, Ioannone, Florenzo, Fornaro, Marco, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos , Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain , Limaye, Vidya , Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Ravichandran, Naveen , Schreiber, Karen , Gupta, Latika , Naveen, R , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Chen, Yi-Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Milchert, Marcin , Joshi, Mrudula , Day, Jessica , Velikova, Tsvetelina , Parodis, Ioannis , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Gracia‐Ramos, Abraham Edgar , Chen, Yi‐Ming , Agarwal, Vishwesh , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, for the COVAD Study, Andréoli, Laura , Ranjan, Rajiv , Pilania, Rakesh Kumar , Sharma, Aman , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira, Kimura, Naoki, Gono, Takahisa , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Maurier, F. , Campagne, Julien , Langguth, Daman , Needham, Merrilee , Srivastav, Nilesh , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Cajas, Javier, Fonseca, João Eurico , Zimba, Olena , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , So, Ho , Ugarte‐Gil, Manuel F. , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | April 2, 2023 | Volume: 62 | Issue: 9 | Pages: e263-e268

10.1093/rheumatology/kead149 | PMID 37004201 Get It

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
Hashim, Mahmoud , Nair, Sandhya, He, Jianming , Ammann, Eric M. , Lam, Annette , Wildgust, Mark, Kumar, Shaji , Fonseca, Rafaël , Facon, Thierry T.F.

Mayo Clinic

The Oncologist | April 1, 2023 | Volume: 28 | Issue: 5 | Pages: e263-e269

10.1093/oncolo/oyad053 | PMID 37002943 Get It

Abstract Background Because patients with newly diagnosed multiple myeloma (NDMM) do not always receive any treatment beyond first-line (1L) therapy, it is imperative that patients receive the best treatment in the 1L setting. However, the optimal initial treatment remains to be identified. We performed a clinical simulation to assess potential outcomes with different treatment sequences. Patients and Methods We used a partitioned survival model to compare overall survival (OS) with (1) daratumumab, lenalidomide, and dexamethasone (D-Rd) in 1L followed by a pomalidomide- or carfilzomib-based regimen in second line (2L) versus (2) bortezomib, lenalidomide, and dexamethasone (VRd) in 1L followed by a daratumumab-based regimen in 2L versus (3) lenalidomide and dexamethasone (Rd) in 1L followed by a daratumumab-based regimen in 2L. Probabilities of transition between health states (1L, 2L+, and death) were based on published clinical data and real-world data from the Flatiron Health database. The proportion of patients discontinuing treatment after 1L (attrition rates) in the base case was estimated with a binomial logistic model using data from the MAIA trial. Results Using D-Rd in 1L conferred a longer median OS compared with delaying daratumumab-based regimens until 2L after VRd or Rd, respectively (8.9 [95% CrI 7.58-10.42] vs. 6.92 [5.92-8.33] or 5.75 [4.50-7.25] years). Results of scenario analyses were consistent with the base case. Conclusion Our simulation, which incorporates clinically representative treatments and attrition rates, supports the use of D-Rd as initial therapy, rather than delaying the use of daratumumab until later lines of therapy, in patients with transplant-ineligible NDMM.
CSF dynamics in long-standing overt ventriculomegaly in adults
Pirina, Alessandro, Jusué-Torres, Ignacio , Desestret, Virginie , Riccioli, L. Albini , Jouanneau, Emmanuel , Manet, Romain , Jusue-Torres, Ignacio , Palandri, Giorgio

Mayo Clinic

Neurosurgical Focus | April 1, 2023 | Volume: 54 | Issue: 4 | Pages: E8

10.3171/2023.1.focus22642 | PMID 37004133 Get It

OBJECTIVE Long-standing overt ventriculomegaly in adults (LOVA) is a form of chronic hydrocephalus and its pathophysiology and treatment remain debated. An analysis of CSF dynamics in this condition has rarely been reported. The aim of this study was to analyze hydrodynamic characteristics of patients with suspected LOVA to discuss its pathophysiological mechanisms and the importance of CSF dynamics analysis for diagnosis and treatment of these patients. METHODS This retrospective cohort study, conducted between May 2018 and October 2022, included adult patients aged > 18 years investigated in a department of neurosurgery through a lumbar infusion study for suspicion of LOVA (n = 23). These patients were then compared with a control cohort explored for suspicion of idiopathic normal pressure hydrocephalus (iNPH; n = 30). Clinical symptoms, radiological findings, and hydrodynamic parameters were analyzed. The authors specifically compared two hydrodynamic parameters: resistance to CSF outflow, or Rout, which relies on CSF resorption, and pressure-volume index (PVI), which reflect overall craniospinal compliance. The lumbar infusion study was considered pathological (confirming the diagnosis of chronic hydrocephalus) when at least one of these two parameters was altered. RESULTS Rout was significantly less frequently increased (cutoff ≥ 12 mm Hg/ml/min) in patients with LOVA (52%) than in those with iNPH (97%; p < 0.001). In contrast, PVI was impaired (cutoff ≤ 25 ml) in both cohorts, i.e., in 61% of patients with LOVA and in 83% of patients with iNPH. Overall, the rate of pathological lumbar infusion study in LOVA (87%) was not statistically different than in iNPH (100%). However, PVI was the only impaired parameter most frequently found in those with LOVA (35%) compared with those with iNPH (3%; p = 0.002). CONCLUSIONS This study suggests that there is a differential CSF dynamics pattern when comparing patients with LOVA versus those with iNPH. A higher proportion of patients with LOVA showed isolated compliance impairment. These findings highlight the utility of CSF dynamics analysis for the evaluation of patients with suspected chronic obstructive hydrocephalus such as LOVA. Future research with larger case series may help define diagnosis and treatment algorithms of chronic obstructive hydrocephalus based on CSF dynamics analysis, in addition to clinical and radiological criteria.
Objective assessment of patients with idiopathic normal pressure hydrocephalus following ventriculoperitoneal shunt placement using activity-monitoring data: pilot study
Jusué-Torres, Ignacio , Pennington, Zach , Ali, Farwa, Graff‐Radford, Neill R. , Cutsforth‐Gregory, Jeremy K. , Graff-Radford, Jonathan, Elder, Benjamin D. , Pennington, Zach , Jusue-Torres, Ignacio , Brown, Desmond , Cogswell, Petrice M. , Ali, Farwa , Jones, David , Graff‐Radford, Jonathan , Kaufman, Kenton R.

Mayo Clinic

Neurosurgical Focus | April 1, 2023 | Volume: 54 | Issue: 4 | Pages: E6

10.3171/2023.1.focus22640 | PMID 37004136 Get It

OBJECTIVE Idiopathic normal pressure hydrocephalus (iNPH) results in significant morbidity in the elderly with symptoms of dementia, gait instability, and urinary incontinence. In well-selected patients, ventriculoperitoneal shunt (VPS) placement often results in clinical improvement. Most postshunt assessments of patients rely on subjective scales. The goal of this study was to assess the utility of remote activity monitoring to provide objective evidence of gait improvement following VPS placement for iNPH. METHODS Patients with iNPH were prospectively enrolled and fitted with 5 activity monitors (on the hip and bilateral thighs and ankles) that they wore for 4 days preoperatively within 30 days of surgery and for 4 days within 30 days postoperatively. Monitors collected continuous data for number of steps, cadence, body position (upright, prone, supine, and lateral decubitus), gait entropy, and the proportion of each day spent active or static. Data were retrieved from the devices and a comparison of pre- and postoperative movement assessment was performed. The gait data were also correlated with formal clinical gait assessments before and after lumbar puncture and with motion analysis laboratory testing at baseline and 1 month and 1 year after VPS placement. RESULTS Twenty patients fulfilled the inclusion and exclusion criteria (median age 76 years). The baseline median number of daily steps was 1929, the median percentage of the day spent inactive was 70%, the median percentage of the day with a static posture was 95%, the median gait velocity was 0.49 m/sec, and the median number of steps required to turn was 8. There was objective improvement in median entropy from pre- to postoperatively, increasing from 0.6 to 0.8 (p = 0.002). There were no statistically significant differences for any of the remaining variables measured by the activity monitors when comparing the preoperative to the 1-month postoperative time point. All variables from motion analysis testing showed statistically significant differences or a trend toward significance at 1 year after VPS placement. Among the significantly correlated variables at baseline, cadence was inversely correlated with percentage of gait cycle spent in the support phase (contact with ground vs swing phase). CONCLUSIONS This pilot study suggests that activity monitoring provides an early objective measure of improvement in gait entropy after VPS placement among patients with iNPH, although a more significant improvement was noted on the detailed clinical gait assessments. Further long-term studies are needed to determine the utility of remote monitoring for assessing gait improvement following VPS placement.
Characteristics of shunt failure in 38,095 adult shunt insertion surgeries: a systematic review and meta-analysis
Isaacs, Albert M. , Yang, Runze , Cadieux, Magalie , Ben‐Israel, David , Sader, Nicholas , Opoku-Darko, Michael, Yong, Heather , Premji, Zahra , Nagel, Sean J. , Hamilton, Mark G. , _, _, _, _, Dasher, Nick, Edwards, R. Lawrence , Golomb, James , Luciano, Mark G. , Katzen, Heather, Zwimpfer, Tom, Nagel, Sean, Frizon, Leonardo A. , _, _, _, _, Dasher, Nickolas , Edwards, Richard, Holubkov, Richard , McKhann, Guy M. , Moghekar, Abhay , Williams, Michael A. , Wisoff, Jeffrey H. , Sader, Nicholas

Mayo Clinic

Neurosurgical Focus | April 1, 2023 | Volume: 54 | Issue: 4 | Pages: E2

10.3171/2023.1.focus22637 | PMID 37004137 Get It

OBJECTIVE The management of excess CSF in patients with hydrocephalus typically requires using a shunt to divert CSF. Unfortunately, there is a high rate of shunt failure despite improvements in device components and insertion techniques. Reoperation is frequently necessary, which contributes to patient harm and increased healthcare costs. While factors affecting shunt failure are well defined in the pediatric population, information regarding adults is lacking. The authors undertook a systematic review and meta-analysis to determine how shunt failure in the adult population is reported and investigated the etiologies of shunt failure. METHODS This review is reported according to PRIMSA and utilized the MEDLINE, Embase, and Google Scholar databases. Abstracts were screened by two independent reviewers, and data were extracted in duplicate by two independent reviewers. Statistical analyses were performed using SPSS and Stata. RESULTS The pooled rates of shunt failure were 10% (95% CI 5%–15%) in studies with a mean follow-up time of less than 1 year, 12% (95% CI 8%–14%) with a follow-up time between 1 and 2 years, and 32% in studies with a follow-up time of 2 years or greater (95% CI 19%–43%). The pooled rate of failure was 17% across all studies. The most common cause of shunt failure was obstruction at 3.0% (95% CI 2%–4%), accounting for 23.2% of shunt failures. Infection was the second most common at 2.8% (95% CI 2%–3%), accounting for 22.5% of shunt failures. The most common location of shunt failure was the distal catheter, with a failure rate of 4.0% (95% CI 3%–5%), accounting for 33.4% of shunt failures. The definition of shunt failure was heterogeneous and varied depending on institutional practices. The combination of symptoms with either CT or MRI was the most frequently reported method for assessing shunt failure. CONCLUSIONS Important variation regarding how to define, investigate, and report shunt failure was identified. The overall shunt failure rate in adults is at least 32% after 2 years, which, while lower than that typically reported in the pediatric population, is significant. The most common causes of shunt failure in adults are infection and obstruction. The most common site of failure occurred at the distal catheter, highlighting the need to develop strategies to both report and mitigate distal shunt failure in adult shunt patients.
Introduction. Adult hydrocephalus: advancements in diagnosis, treatment, and patient outcomes
Hamilton, Mark G. , Israelsson, Hanna , Elder, Benjamin D. , Williams, Michael A. , Palandri, Giorgio

Mayo Clinic

Neurosurgical Focus | April 1, 2023 | Volume: 54 | Issue: 4 | Pages: E1

10.3171/2023.1.focus22641 | PMID 37004135 Get It